AssayIndex
HYB cross-section

HYB by compound

HYB records split by compound, with the index-wide comparison for the same compound beside each one. 30 compounds, 332 records. Cells below n=3 print their raw values instead of a median.

30 compounds332 records
CompoundClassReportsHYB median %Index median %Δ (pp)SpecPass %
TirzepatideIncretin5698.9098.54+0.3697.0100
RetatrutideIncretin3498.5098.44+0.0696.5100
BPC-157Tissue-repair2399.6399.32+0.3198.0100
GHRP-2Growth-hormone2399.6499.43+0.2199.0100
SemaglutideIncretin1998.6298.91-0.2997.0100
CJC-1295 (no DAC)Growth-hormone1599.3098.88+0.4298.0100
GHRP-6Growth-hormone1499.8699.57+0.2999.0100
SurvodutideIncretin1498.7598.60+0.1596.5100
SelankNeuroactive1499.8199.55+0.2699.0100
ExenatideIncretin1398.7398.84-0.1198.0100
Melanotan IIMelanocortin-receptor1199.7899.44+0.3498.5100
EpitalonShort1099.6999.50+0.1999.0100
Enclomiphene citrateNon-peptide1099.6698.97+0.6998.5100
Humanin (HNG)Metabolic1099.6799.16+0.5197.5100
MOTS-cMetabolic899.6999.28+0.4198.0100
Larazotide acetateTissue-repair899.6999.690.0098.5100
SS-31 (Elamipretide)Metabolic7 n=799.8599.47+0.3898.5100
HexarelinGrowth-hormone6 n=699.9399.59+0.3499.0100
DihexaNeuroactive5 n=599.7899.64+0.1498.5100
TB-500Tissue-repair5 n=599.9399.50+0.4498.5100
ARA-290Tissue-repair5 n=599.6099.64-0.0498.0100
TriptorelinHypothalamic4 n=499.3698.52+0.8498.5100
MGFGrowth-hormone3 n=399.6299.34+0.2897.5100
PT-141 (Bremelanotide)Melanocortin-receptor3 n=399.3299.33-0.0198.5100
IGF-1 LR3Growth-hormone3 n=399.0797.97+1.1095.0100
IpamorelinGrowth-hormone3 n=399.8499.52+0.3399.0100
CJC-1295 with DACGrowth-hormone2 n=2n<398.9797.5100
L-Glutathione (reduced)Short2 n=2n<399.2098.5100
KPVTissue-repair1 n=1n<399.5799.0100
MK-677 (Ibutamoren mesylate)Non-peptide1 n=1n<399.4298.5100
97.397.898.298.799.299.7100.1TirzepatideTirzepatide: Q1 98.41, median 98.90, Q3 99.64, n=56n=56RetatrutideRetatrutide: Q1 98.34, median 98.50, Q3 98.65, n=34outlier 97.49outlier 97.67outlier 99.30n=34BPC-157BPC-157: Q1 98.49, median 99.63, Q3 99.84, n=23n=23GHRP-2GHRP-2: Q1 99.56, median 99.64, Q3 99.92, n=23n=23SemaglutideSemaglutide: Q1 98.47, median 98.62, Q3 98.74, n=19outlier 98.04outlier 99.64n=19CJC-1295 (no DAC)CJC-1295 (no DAC): Q1 99.19, median 99.30, Q3 99.64, n=15n=15GHRP-6GHRP-6: Q1 99.77, median 99.86, Q3 99.93, n=14n=14SurvodutideSurvodutide: Q1 98.64, median 98.75, Q3 98.91, n=14n=14SelankSelank: Q1 99.66, median 99.81, Q3 99.92, n=14n=14ExenatideExenatide: Q1 98.68, median 98.73, Q3 98.95, n=13outlier 99.39outlier 99.44outlier 99.72n=13Melanotan IIMelanotan II: Q1 99.69, median 99.78, Q3 99.83, n=11outlier 99.42n=11EpitalonEpitalon: Q1 99.57, median 99.69, Q3 99.84, n=10n=10Enclomiphene citrateEnclomiphene citrate: Q1 99.24, median 99.66, Q3 99.92, n=10n=10Humanin (HNG)Humanin (HNG): Q1 99.59, median 99.67, Q3 99.91, n=10n=10 Purity (% area)
Figure. Distribution per compound where n ≥ 4. Rows are ordered by coverage, not by result.

Which of these lines HYB actually stocks

Coverage here reflects what has been submitted to the index, not what is on the catalogue. Shenzhen Hybio Pharmaceutical Co., Ltd. lists considerably more than the 30 compounds above. Of those 30, 21 have been seen arriving from a domestic warehouse rather than as a cross-border consignment — that is the whole of what the index can say about which lines are held in regional stock, and it is a record of what was submitted, not a stock position. The catalogue and the current stock position are on the supplier's own site.

Browse the HYB catalogue at hybiopharmaceutical.com →